199 related articles for article (PubMed ID: 12080289)
1. Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users.
Stuerenburg HJ; Petersen K; Bäumer T; Rosenkranz M; Buhmann C; Thomasius R
Neuro Endocrinol Lett; 2002 Jun; 23(3):259-61. PubMed ID: 12080289
[TBL] [Abstract][Full Text] [Related]
2. [A case of acute psychotic episode after a single dose of ecstasy].
Vaiva G; Bailly D; Boss V; Thomas P; Lestavel P; Goudemand M
Encephale; 2001; 27(2):198-202. PubMed ID: 11407274
[TBL] [Abstract][Full Text] [Related]
3. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI
Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661
[TBL] [Abstract][Full Text] [Related]
4. Plasma amino acids in ecstasy users.
Stuerenburg HJ; Petersen K; Buhmann C; Rosenkranz M; Baeumer T; Thomasius R
Neuro Endocrinol Lett; 2003 Oct; 24(5):348-9. PubMed ID: 14647011
[TBL] [Abstract][Full Text] [Related]
5. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
6. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
7. [Reduced sympathetic nervous system activity during the cluster period of cluster-headache].
Strittmatter M; Hamann GF; Blaes F; Grauer M; Fischer C; Hoffmann KH
Schweiz Med Wochenschr; 1996 Jun; 126(24):1054-61. PubMed ID: 8701243
[TBL] [Abstract][Full Text] [Related]
8. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
Gouzoulis-Mayfrank E; Daumann J
Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
[TBL] [Abstract][Full Text] [Related]
9. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Nagaoka S; Iwamoto N; Arai H
Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
[TBL] [Abstract][Full Text] [Related]
10. Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment.
Nigmatullina RR; Kirillova VV; Jourjikiya RK; Mukhamedyarov MA; Kudrin VS; Klodt PM; Palotás A
Cardiology; 2009; 113(4):277-86. PubMed ID: 19270454
[TBL] [Abstract][Full Text] [Related]
11. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of MDMA (Ecstasy) on the human central nervous system revealed by visual evoked potentials.
Casco C; Forcella M; Beretta G; Grieco A; Campana G
Addict Biol; 2005 Jun; 10(2):187-95. PubMed ID: 16191672
[TBL] [Abstract][Full Text] [Related]
13. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
Soar K; Turner JJ; Parrott AC
J Psychopharmacol; 2006 May; 20(3):417-24. PubMed ID: 16574716
[TBL] [Abstract][Full Text] [Related]
14. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ
Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
[TBL] [Abstract][Full Text] [Related]
15. Experimentally induced aggressive behavior in subjects with 3,4-methylenedioxy-methamphetamine ("Ecstasy") use history: psychobiological correlates.
Gerra G; Zaimovic A; Ampollini R; Giusti F; Delsignore R; Raggi MA; Laviola G; Macchia T; Brambilla F
J Subst Abuse; 2001; 13(4):471-91. PubMed ID: 11775077
[TBL] [Abstract][Full Text] [Related]
16. Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study.
Daumann J; Fischermann T; Heekeren K; Thron A; Gouzoulis-Mayfrank E
Biol Psychiatry; 2004 Sep; 56(5):349-55. PubMed ID: 15336517
[TBL] [Abstract][Full Text] [Related]
17. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use.
Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J
Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163
[TBL] [Abstract][Full Text] [Related]
18. [Psychiatric and cognitive long-term effects of ecstasy].
Høiseth G; Løvåsdal Ø; Titze TK; Bramness JG; Bachs L
Tidsskr Nor Laegeforen; 2006 Feb; 126(5):596-8. PubMed ID: 16505868
[TBL] [Abstract][Full Text] [Related]
19. Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study.
Daumann J; Till B; Fischermann T; Rezk M; Gouzoulis-Mayfrank E
J Psychopharmacol; 2006 Mar; 20(2):236-44. PubMed ID: 16510481
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature.
Uys JD; Niesink RJ
Drug Alcohol Rev; 2005 Jul; 24(4):359-68. PubMed ID: 16234132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
